Contribute Try STAT+ Today

Three years ago, the biotech firm Loxo Oncology purchased a promising blood cancer pill for $40 million — part of a transaction that involved a near-bankruptcy, entrepreneurs with a keen eye, and a red-eye flight from Chicago to London. Now the medicine could go down as one of the great deals in biotech history, pending further data.

Eli Lilly, which acquired Loxo for $8 billion in January 2019, presented new data on the drug, LOXO-305, at this year’s annual meeting of the American Society of Hematology, which opened this past weekend. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.